ASTH Quote, Financials, Valuation and Earnings

Cryo-Cell International, Inc. has a net margin of 0.11% compared to Astrana Health, Inc.'s net margin of 9.58%. Astrana Health, Inc.'s return on equity of 1.85% beat Cryo-Cell International, Inc.'s return on equity of --.

Astrana Health, Inc. has a consensus price target of $35.6667, signalling upside risk potential of 89.92%. On the other hand Cryo-Cell International, Inc. has an analysts' consensus of $8.50 which suggests that it could grow by 148.03%. Given that Cryo-Cell International, Inc. has higher upside potential than Astrana Health, Inc., analysts believe Cryo-Cell International, Inc. is more attractive than Astrana Health, Inc..

Astrana Health, Inc. has a beta of 0.904, which suggesting that the stock is 9.555% less volatile than S&P 500. In comparison Cryo-Cell International, Inc. has a beta of 0.701, suggesting its less volatile than the S&P 500 by 29.861%.

Astrana Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International, Inc. offers a yield of 18.97% to investors and pays a quarterly dividend of $0.15 per share. Astrana Health, Inc. pays -- of its earnings as a dividend. Cryo-Cell International, Inc. pays out 510.2% of its earnings as a dividend.

Astrana Health, Inc. quarterly revenues are $956M, which are larger than Cryo-Cell International, Inc. quarterly revenues of $7.8M. Astrana Health, Inc.'s net income of $1.1M is higher than Cryo-Cell International, Inc.'s net income of $749.4K. Notably, Astrana Health, Inc.'s price-to-earnings ratio is 98.84x while Cryo-Cell International, Inc.'s PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health, Inc. is 0.32x versus 0.88x for Cryo-Cell International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novo Integrated Sciences, Inc. has a net margin of 0.11% compared to Astrana Health, Inc.'s net margin of -86.61%. Astrana Health, Inc.'s return on equity of 1.85% beat Novo Integrated Sciences, Inc.'s return on equity of -49.15%.

Astrana Health, Inc. has a consensus price target of $35.6667, signalling upside risk potential of 89.92%. On the other hand Novo Integrated Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Astrana Health, Inc. has higher upside potential than Novo Integrated Sciences, Inc., analysts believe Astrana Health, Inc. is more attractive than Novo Integrated Sciences, Inc..

Astrana Health, Inc. has a beta of 0.904, which suggesting that the stock is 9.555% less volatile than S&P 500. In comparison Novo Integrated Sciences, Inc. has a beta of 1.479, suggesting its more volatile than the S&P 500 by 47.909%.

Astrana Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Integrated Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astrana Health, Inc. pays -- of its earnings as a dividend. Novo Integrated Sciences, Inc. pays out -- of its earnings as a dividend.

Astrana Health, Inc. quarterly revenues are $956M, which are larger than Novo Integrated Sciences, Inc. quarterly revenues of $3.2M. Astrana Health, Inc.'s net income of $1.1M is higher than Novo Integrated Sciences, Inc.'s net income of -$2.7M. Notably, Astrana Health, Inc.'s price-to-earnings ratio is 98.84x while Novo Integrated Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health, Inc. is 0.32x versus 0.00x for Novo Integrated Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pacific Health Care Organization, Inc. has a net margin of 0.11% compared to Astrana Health, Inc.'s net margin of 14.05%. Astrana Health, Inc.'s return on equity of 1.85% beat Pacific Health Care Organization, Inc.'s return on equity of 11.97%.

Astrana Health, Inc. has a consensus price target of $35.6667, signalling upside risk potential of 89.92%. On the other hand Pacific Health Care Organization, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Astrana Health, Inc. has higher upside potential than Pacific Health Care Organization, Inc., analysts believe Astrana Health, Inc. is more attractive than Pacific Health Care Organization, Inc..

Astrana Health, Inc. has a beta of 0.904, which suggesting that the stock is 9.555% less volatile than S&P 500. In comparison Pacific Health Care Organization, Inc. has a beta of 0.126, suggesting its less volatile than the S&P 500 by 87.368%.

Astrana Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacific Health Care Organization, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.10 per share. Astrana Health, Inc. pays -- of its earnings as a dividend. Pacific Health Care Organization, Inc. pays out -- of its earnings as a dividend.

Astrana Health, Inc. quarterly revenues are $956M, which are larger than Pacific Health Care Organization, Inc. quarterly revenues of $1.6M. Astrana Health, Inc.'s net income of $1.1M is higher than Pacific Health Care Organization, Inc.'s net income of $223K. Notably, Astrana Health, Inc.'s price-to-earnings ratio is 98.84x while Pacific Health Care Organization, Inc.'s PE ratio is 11.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health, Inc. is 0.32x versus 2.53x for Pacific Health Care Organization, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

WW International has a net margin of 0.11% compared to Astrana Health, Inc.'s net margin of -38.91%. Astrana Health, Inc.'s return on equity of 1.85% beat WW International's return on equity of --.

Astrana Health, Inc. has a consensus price target of $35.6667, signalling upside risk potential of 89.92%. On the other hand WW International has an analysts' consensus of $1.10 which suggests that it could grow by 340.71%. Given that WW International has higher upside potential than Astrana Health, Inc., analysts believe WW International is more attractive than Astrana Health, Inc..

Astrana Health, Inc. has a beta of 0.904, which suggesting that the stock is 9.555% less volatile than S&P 500. In comparison WW International has a beta of 1.298, suggesting its more volatile than the S&P 500 by 29.755%.

Astrana Health, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. WW International offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astrana Health, Inc. pays -- of its earnings as a dividend. WW International pays out -- of its earnings as a dividend.

Astrana Health, Inc. quarterly revenues are $956M, which are larger than WW International quarterly revenues of $186.6M. Astrana Health, Inc.'s net income of $1.1M is higher than WW International's net income of -$72.6M. Notably, Astrana Health, Inc.'s price-to-earnings ratio is 98.84x while WW International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astrana Health, Inc. is 0.32x versus 0.03x for WW International. Usually stocks with elevated PS ratios are considered overvalued.